BR112019020335A2 - composições e métodos para tratar sinucleinopatias - Google Patents

composições e métodos para tratar sinucleinopatias Download PDF

Info

Publication number
BR112019020335A2
BR112019020335A2 BR112019020335A BR112019020335A BR112019020335A2 BR 112019020335 A2 BR112019020335 A2 BR 112019020335A2 BR 112019020335 A BR112019020335 A BR 112019020335A BR 112019020335 A BR112019020335 A BR 112019020335A BR 112019020335 A2 BR112019020335 A2 BR 112019020335A2
Authority
BR
Brazil
Prior art keywords
seq
amino acid
synuclein
antibody
acid residues
Prior art date
Application number
BR112019020335A
Other languages
English (en)
Portuguese (pt)
Inventor
Kandadi Muralidharan Kumar
Penner Natasha
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of BR112019020335A2 publication Critical patent/BR112019020335A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR112019020335A 2017-03-31 2018-03-30 composições e métodos para tratar sinucleinopatias BR112019020335A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479818P 2017-03-31 2017-03-31
US201762528790P 2017-07-05 2017-07-05
PCT/IB2018/052236 WO2018178950A1 (en) 2017-03-31 2018-03-30 Compositions and methods for treating synucleinopathies

Publications (1)

Publication Number Publication Date
BR112019020335A2 true BR112019020335A2 (pt) 2020-04-28

Family

ID=62092178

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019020335A BR112019020335A2 (pt) 2017-03-31 2018-03-30 composições e métodos para tratar sinucleinopatias

Country Status (13)

Country Link
US (1) US20200377579A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630815A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020512368A (cg-RX-API-DMAC7.html)
KR (1) KR20200026789A (cg-RX-API-DMAC7.html)
CN (1) CN110997715A (cg-RX-API-DMAC7.html)
AU (1) AU2018242626A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019020335A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058304A1 (cg-RX-API-DMAC7.html)
IL (1) IL269637A (cg-RX-API-DMAC7.html)
JO (1) JOP20190227A1 (cg-RX-API-DMAC7.html)
MA (1) MA48730A (cg-RX-API-DMAC7.html)
SG (1) SG11201908672WA (cg-RX-API-DMAC7.html)
WO (1) WO2018178950A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
CA3076313A1 (en) * 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
BR112021006123A2 (pt) * 2018-10-19 2021-07-20 Janssen Vaccines & Prevention B.V. anticorpos anti-sinucleína
MX2022006676A (es) * 2019-12-04 2022-07-05 Ac Immune Sa Nuevas moleculas para terapia y diagnostico.
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
TW202227131A (zh) 2020-09-10 2022-07-16 愛爾蘭商普羅佘納生物科技有限公司 帕金森氏症之治療
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies
JP2026506882A (ja) * 2023-02-06 2026-02-27 クリエイティブ バイオ-ぺプタイズ インコーポレイテッド 神経学的障害を処置するためのペプチド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
HRP20150831T1 (hr) * 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
PL2723379T3 (pl) * 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн

Also Published As

Publication number Publication date
CN110997715A (zh) 2020-04-10
JP2020512368A (ja) 2020-04-23
SG11201908672WA (en) 2019-10-30
MA48730A (fr) 2020-04-08
WO2018178950A1 (en) 2018-10-04
US20200377579A1 (en) 2020-12-03
JOP20190227A1 (ar) 2019-09-30
CA3058304A1 (en) 2018-10-04
IL269637A (en) 2019-11-28
KR20200026789A (ko) 2020-03-11
AU2018242626A1 (en) 2019-10-10
EP3630815A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
US20200377579A1 (en) Compositions and methods for treating synucleinopathies
JP6900500B2 (ja) 抗N3pGluアミロイドベータペプチド抗体およびその使用
US12145988B2 (en) Anti-TREM-2 agonist antibodies
JP4977625B2 (ja) 抗aベータ抗体製剤
US8926974B2 (en) Methods of treating a tauopathy
US9895429B2 (en) Antibodies that bind amyloid oligomers
CN104822389B (zh) 识别α-突触核蛋白的抗体
US11655289B2 (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
US12116407B2 (en) Methods of treating neurodegenerative diseases
RS60883B1 (sr) Metodi lečenja tauopatije
US10947311B2 (en) VCAM-1 mediated methods and compositions for treating aging-associated impairments
HK1108132B (en) Anti a beta antibody formulation
HK1163504A (en) Anti a beta antibody formulation
WO2010024432A1 (ja) 中枢神経損傷治療剤

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2716 DE 24-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.